Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment

Sandra Ann Springer, Shu Chen, Frederick L Altice, Sandra Ann Springer, Shu Chen, Frederick L Altice

Abstract

HIV-infected prisoners fare poorly after release. Though rarely available, opioid agonist therapy (OAT) may be one way to improve HIV and substance abuse treatment outcomes after release. Of the 69 HIV-infected prisoners enrolled in a randomized controlled trial of directly administered antiretroviral therapy, 48 (70%) met DSM-IV criteria for opioid dependence. Of these, 30 (62.5%) selected OAT, either as methadone (N = 7, 14.5%) or buprenorphine/naloxone (BPN/NLX; N = 23, 48.0%). Twelve-week HIV and substance abuse treatment outcomes are reported as a sub-study for those selecting BPN/NLX. Retention was high: 21 (91%) completed BPN/NLX induction and 17 (74%) remained on BPN/NLX after 12 weeks. Compared with baseline, the proportion with a non-detectable viral load (61% vs 63% log(10) copies/mL) and mean CD4 count (367 vs 344 cells/mL) was unchanged at 12 weeks. Opiate-negative urine testing remained 83% for the 21 who completed induction. Using means from 10-point Likert scales, opioid craving was reduced from 6.0 to 1.8 within 3 days of BPN/NLX induction and satisfaction remained high at 9.5 throughout the 12 weeks. Adverse events were few and mild. BPN/NLX therapy was acceptable, safe and effective for both HIV and opioid treatment outcomes among released HIV-infected prisoners. Future randomized controlled trials are needed to affirm its benefit in this highly vulnerable population.

Figures

FIGURE 1.
FIGURE 1.
Subject allocation.
FIGURE 2.
FIGURE 2.
HIV treatment outcomes.
FIGURE 3.
FIGURE 3.
Opiate craving and satisfaction with buprenorphine treatment.
FIGURE 4.
FIGURE 4.
Percent of positive urine toxicology tests over time.

References

    1. Spaulding AC, Seals RM, Page MJ, Brzozowski AK, Rhodes W, Hammett TM. HIV/AIDS among inmates of and releasees from US correctional facilities, 2006: declining share of epidemic but persistent public health opportunity. PLoS ONE. 2009;4(11):e7558. doi: 10.1371/journal.pone.0007558.
    1. Hammett TM, Harmon MP, Rhodes W. The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. Am J Public Health. 2002;92(11):1789–1794. doi: 10.2105/AJPH.92.11.1789.
    1. Centers for Disease Control (CDC) Decrease in AIDS-related mortality in a state correctional system—New York, 1995–1998. MMWR Morb Mortal Wkly Rep. 1999;47(51–52):1115–1117.
    1. Springer S, Friedland G, Doros G, Pesanti E, Altice FL. Antiretroviral treatment regimen outcomes among HIV-infected prisoners. New Haven: Yale AIDS Program; 2007.
    1. Levasseur L, Marzo J, Ross N, Blatier C. Frequency of re-incarcerations in the same detention center: role of substitution therapy. A preliminary retrospective analysis. Ann Med Interne. 2002;153(3 Suppl):1S14–1S19.
    1. Kinlock TW, Battjes RJ, Schwartz RP. A novel opioid maintenance program for prisoners: preliminary findings. J Subst Abuse Treat. 2002;22(3):141–147. doi: 10.1016/S0740-5472(02)00226-X.
    1. Nurco D, Hanlon T, Kinlock TW. Recent research on the relationship between illicit drug use and crime. Behav Sci Law. 1991;9:221–242. doi: 10.1002/bsl.2370090303.
    1. Wexler HK, Lipton D, Johnson BA. A criminal justice system strategy for treating cocaine-heroin abusing offenders in custody. Washington, DC: US Department of Justice, National Institute of Justice, Office of Communication and Research Utilization; 1988.
    1. Binswanger IA, Stern MF, Deyo RA, et al. Release from prison—a high risk of death for former inmates. N Engl J Med. 2007;356(2):157–165. doi: 10.1056/NEJMsa064115.
    1. Baillargeon J, Giordano TP, Rich JD, et al. Accessing antiretroviral therapy following release from prison. JAMA. 2009;301(8):848–857. doi: 10.1001/jama.2009.202.
    1. Springer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. Clin Infect Dis. 2004;38(12):1754–1760. doi: 10.1086/421392.
    1. Stephenson BL, Wohl DA, Golin CE, Tien HC, Stewart P, Kaplan AH. Effect of release from prison and re-incarceration on the viral loads of HIV-infected individuals. Public Health Rep. 2005;120(1):84–88.
    1. Stephenson BL, Wohl DA, McKaig R, et al. Sexual behaviours of HIV-seropositive men and women following release from prison. Int J STD AIDS. 2006;17(2):103–108. doi: 10.1258/095646206775455775.
    1. Council of State Governments (CSG) Report of the Re-Entry Policy Council: charting the safe adn successful return of prisoners to the community. New York: National Institute of Corrections, Bureau of Prisons, US Department of Justice, USA government; 2003.
    1. Gaes G, Flanigan TP, Montiuk L, Stewart L. Adult correctional treatment. In: Tonry M, Petersilia J, editors. Prisons: crime and justice: a review of reserach. Chicago: University of Chicago Press; 1999. pp. 361–425.
    1. Visher C, Farrell J. Chicago communities and prisoner re-entry. Washington: The Urban Institute Justice Policy Center; 2005.
    1. Amato L, Minozzi S, Davoli M, Vecchi S, Ferri MM, Mayet S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev. (3):CD005031, 2008.
    1. World Health Organization, United Nations Office On Drugs and Crime, and the Joint United Nations Programme on HIV/AIDS . Joint position paper on substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention. Geneva: WHO; 2004.
    1. Karberg J, James D. Substance Dependence, Abuse, and Treatment of Jail Inmates, 2002. Washington, D.C. NCJ 209588, 2005.
    1. Mumola C. Substance abuse and treatment, state and federal prisoners (1997). Bureau of Justice Statistics Special Report, NCJ 172871, USDepartment of Justice, Office of Justice Programs, Washington, DC. pp 1–16.
    1. Chandler RK, Fletcher BW, Volkow ND. Treating drug abuse and addiction in the criminal justice system: improving public health and safety. JAMA. 2009;301(2):183–190. doi: 10.1001/jama.2008.976.
    1. Smith-Rohrberg D, Bruce RD, Altice FL. Review of corrections-based therapy for opiate-depenndent patients: Implications for buprenorphine treatment among correctional populations. J Drug Issues. 2004;34(2):451–480.
    1. Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr. 2006;41(5):563–572. doi: 10.1097/.
    1. Sheehan D, Lecrubier Y, Harnett-Sheehan K, et al. Reliability and validity of the MINI International Neuropsychiatric Interview (M.I.N.I.): according to the SCID-P. Eur Psychiatr. 1997;12:232–241. doi: 10.1016/S0924-9338(97)83297-X.
    1. McLellan AT, Kushner H, Metzger D, et al. The fifth edition of the addiction severity index. J Subst Abuse Treat. 1992;9(3):199–213. doi: 10.1016/0740-5472(92)90062-S.
    1. Rosen C, Henson B, Finney J, Moos R. Consistency of self-administered and interview-based Addiction Severity Index composite scores. Addiction. 2000;95(3):419–425. doi: 10.1046/j.1360-0443.2000.95341912.x.
    1. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption—II. Addiction. 1993;88(6):791–804. doi: 10.1111/j.1360-0443.1993.tb02093.x.
    1. Copenhaver MM, Bruce RD, Altice FL. Behavioral counseling content for optimizing the use of buprenorphine for treatment of opioid dependence in community-based settings: a review of the empirical evidence. Am J Drug Alcohol Abuse. 2007;33(5):643–654. doi: 10.1080/00952990701522674.
    1. Nurco D, Hanlon T, Shaffer J, Kinlock T, Duszynski K, Stephenson P. Differences among treatment clinic types in attitudes toward narcotic addiction. J Nerv Ment Dis. 1988;176(12):71.
    1. Kinlock TW, Gordon MS, Schwartz RP, O'Grady KE. A study of methadone maintenance for male prisoners: 3-month postrelease outcomes. Crim Justice Behav. 2008;35(1):34–47. doi: 10.1177/0093854807309111.
    1. Sullivan LE, Barry D, Moore BA, et al. A trial of integrated buprenorphine/naloxone and HIV clinical care. Clin Infect Dis. 2006;43(Suppl 4):S184–S190. doi: 10.1086/508182.
    1. Garcia C, Correa G, Hernandez-Viver A, et al. Buprenorphine-naloxone treatment for pre-release opioid-dependent inmates in Puerto Rico. J Addiction Med. 2007;1:126–132. doi: 10.1097/ADM.0b013e31814b8880.
    1. Sullivan LE, Bruce RD, Haltiwanger D, et al. Initial strategies for integrating buprenorphine into HIV care settings in the United States. Clin Infect Dis. 2006;43(Suppl 4):S191–S196. doi: 10.1086/508183.
    1. Durand E. Changes in high-dose buprenorphine maintenance therapy at the Fleury-Merogis (France) prison since 1996. Ann Med Interne (Paris) 2001;152(Suppl 7):9–14.
    1. Moatti J, Carrieri M, Spire B, Gastault J, Cassuto J, Moreau J. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. AIDS And Behavior. 2000;14:151–155.
    1. Center for Substance Abuse Treatment . Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) Series 40. Rockville: Substance Abuse and Mental Health Services Administration, US Department of Health and Human Services ; 2004.
    1. McCance-Katz EF, Moody DE, Morse GD, et al. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend. 2007;91(2–3):269–278. doi: 10.1016/j.drugalcdep.2007.06.007.
    1. McCance-Katz EF, Moody DE, Morse GD, et al. Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin Infect Dis. 2006;43(Suppl 4):S224–S234. doi: 10.1086/508187.
    1. Douaihy AB, Jou RJ, Gorske T, Salloum IM. Triple diagnosis: dual diagnosis and HIV disease, part 2. AIDS Read. 2003;13(8):375–382.
    1. Bruce R, Altice F. Editorial comment: why treat three conditions when it is one patient? AIDS Read. 2003;13(8):378–379.
    1. Springer S, Altice F. Improving the care for HIV-infected prisoners: an integrated prison-release health model. In: Greifinger R, editor. Public health behind bars: from prisons to communities. New York: Springer; 2007.
    1. Springer SA, Altice FL. Managing HIV/AIDS in correctional settings. Current HIV/AIDS reports. 2005;2(4):165–170. doi: 10.1007/s11904-005-0011-9.
    1. Zaller ND, Holmes L, Dyl AC, et al. Linkage to treatment and supportive services among HIV-positive ex-offenders in Project Bridge. J Health Care Poor Underserved. 2008;19(2):522–531. doi: 10.1353/hpu.0.0030.
    1. Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess. 2007;11(9):1–171.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅